BioMark Diagnostics (TSE:BUX)
CNQX:BUX
Holding TSE:BUX?
Track your performance easily

BioMark Diagnostics (BUX) Financial Statements

3 Followers

BioMark Diagnostics Financial Overview

BioMark Diagnostics's market cap is currently ―. The company's EPS TTM is C$-0.018; its P/E ratio is -13.24; BioMark Diagnostics is scheduled to report earnings on November 28, 2024, and the estimated EPS forecast is C$―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total RevenueC$ 38.31KC$ 39.80KC$ 41.54KC$ 42.13KC$ 39.75K
Gross ProfitC$ 38.31KC$ 39.80KC$ 41.54KC$ 42.13KC$ 39.75K
EBITC$ -604.30KC$ -339.86KC$ -386.69KC$ -192.12KC$ -393.55K
EBITDAC$ -546.54KC$ -239.01KC$ -287.65KC$ -101.60KC$ -290.78K
Net Income Common StockholdersC$ -623.28KC$ -391.31KC$ -406.76KC$ -210.46KC$ -418.86K
Balance Sheet-
Cash, Cash Equivalents and Short-Term InvestmentsC$ 141.36KC$ 156.75KC$ 313.03KC$ 168.44KC$ 175.24K
Total AssetsC$ 1.01MC$ 1.09MC$ 1.35MC$ 632.24KC$ 722.81K
Total DebtC$ 721.96KC$ 805.93KC$ 1.08MC$ 516.44KC$ 737.64K
Net DebtC$ 580.60KC$ 649.18KC$ 770.53KC$ 347.99KC$ 562.41K
Total LiabilitiesC$ 1.66MC$ 1.70MC$ 1.91MC$ 1.78MC$ 1.86M
Stockholders EquityC$ -649.61KC$ -609.61KC$ -559.77KC$ -1.15MC$ -1.14M
Cash Flow-
Free Cash FlowC$ -323.20KC$ -215.70KC$ -508.63KC$ -12.81KC$ -249.77K
Operating Cash FlowC$ -320.69KC$ -214.47KC$ -506.43KC$ -11.85KC$ -249.77K
Investing Cash FlowC$ -2.51KC$ -1.24KC$ -2.20KC$ -957.00-
Financing Cash FlowC$ 307.81KC$ 59.42KC$ 653.22KC$ 6.02KC$ 352.97K
Currency in CAD

BioMark Diagnostics Earnings and Revenue History

BioMark Diagnostics Debt to Assets

BioMark Diagnostics Cash Flow

BioMark Diagnostics Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis